Jeffrey L Bennett

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3997899/publications.pdf

Version: 2024-02-01

79 papers	8,941 citations	57758 44 h-index	66911 78 g-index
81 all docs	81 docs citations	81 times ranked	6284 citing authors

#	Article	IF	Citations
1	The changing landscape of optic neuritis: a narrative review. Journal of Neurology, 2022, 269, 111-124.	3.6	28
2	AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2022, 57, 103356.	2.0	16
3	A new form of axonal pathology in a spinal model of neuromyelitis optica. Brain, 2022, 145, 1726-1742.	7.6	10
4	Evaluation of Plasma Neurofilament Light Chain Levels as a Biomarker of Neuronal Injury in the Active and Chronic Phases of Autoimmune Neurologic Disorders. Frontiers in Neurology, 2022, 13, 689975.	2.4	6
5	Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Associated Disease. JAMA Neurology, 2022, 79, 518.	9.0	39
6	In utero exposure to maternal antiâ€“aquaporin-4 antibodies alters brain vasculature and neural dynamics in male mouse offspring. Science Translational Medicine, 2022, 14, eabe9726.	12.4	11
7	Heterogeneity of Acetylcholine Receptor Autoantibodyâ€“Mediated Complement Activity in Patients With Myasthenia Gravis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	21
8	Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients. Neurotherapeutics, 2021, 18, 364-377.	4.4	20
9	Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. Multiple Sclerosis Journal, 2021, 27, 2052-2061.	3.0	11
10	Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	20
11	Blood-brain barrier resealing in neuromyelitis optica occurs independently of astrocyte regeneration. Journal of Clinical Investigation, 2021, 131, .	8.2	18
12	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. Annals of Neurology, 2021, 89, 895-910.	5.3	72
13	Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?. Journal of Neuroinflammation, 2021, 18, 121.	7.2	22
14	A Longitudinal, Observational Analysis of Neuronal Injury Biomarkers in a Case Report of a Patient With Paraneoplastic Anti-CRMP5 Antibody-Associated Transverse Myelitis. Frontiers in Neurology, 2021, 12, 691509.	2.4	4
15	Clinical Features and Outcomes of Pediatric Monophasic and Recurrent Idiopathic Optic Neuritis. Journal of Child Neurology, 2020, 35, 77-83.	1.4	5
16	Affinity-matured â€˜aquaporumabâ€™ anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders. Neuropharmacology, 2020, 162, 107827.	4.1	32
17	Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	112
18	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Multiple Sclerosis and Related Disorders, 2020, 44, 102251.	2.0	110

#	Article	IF	Citations
19	Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology, 2020, 95, e111-e120.	1.1	140
20	Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurology, The, 2020, 19, 402-412.	10.2	278
21	Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurology, The, 2020, 19, 391-401.	10.2	183
22	Induction of aquaporin 4-reactive antibodies in Lewis rats immunized with aquaporin 4 mimotopes. Acta Neuropathologica Communications, 2020, 8, 49.	5.2	5
23	Novel clinical features of glycine receptor antibody syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e592.	6.0	43
24	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet, The, 2019, 394, 1352-1363.	13.7	433
25	Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. Brain, 2019, 142, 1598-1615.	7.6	62
26	Concentration-dependent effects of CSF1R inhibitors on oligodendrocyte progenitor cells ex vivo and in vivo. Experimental Neurology, 2019, 318, 32-41.	4.1	53
27	Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica. Journal of Clinical Investigation, 2019, 129, 2000-2013.	8.2	81
28	Distinct patterns of glia repair and remyelination in antibodyâ€mediated demyelination models of multiple sclerosis and neuromyelitis optica. Glia, 2018, 66, 2575-2588.	4.9	23
29	Mutations of Recombinant Aquaporin-4 Antibody in the Fc Domain Can Impair Complement-Dependent Cellular Cytotoxicity and Transplacental Transport. Frontiers in Immunology, 2018, 9, 1599.	4.8	4
30	Comparative molecular dynamics study of neuromyelitis optica-immunoglobulin G binding to aquaporin-4 extracellular domains. Biochimica Et Biophysica Acta - Biomembranes, 2017, 1859, 1326-1334.	2.6	9
31	Determining the Spatial Relationship ofÂMembrane-Bound Aquaporin-4 Autoantibodies by STED Nanoscopy. Biophysical Journal, 2017, 112, 1692-1702.	0.5	4
32	CNS Aquaporinâ€4â€specific B cells connect with multiple Bâ€cell compartments in neuromyelitis optica spectrum disorder. Annals of Clinical and Translational Neurology, 2017, 4, 369-380.	3.7	53
33	Dural sinus stenting for idiopathic intracranial hypertension: factors associated with hemodynamic failure and management with extended stenting. Journal of NeuroInterventional Surgery, 2017, 9, 867-874.	3.3	41
34	Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica. Science Translational Medicine, 2017, 9, .	12.4	110
35	Efficacy of Polyvalent Human Immunoglobulins in an Animal Model of Neuromyelitis Optica Evoked by Intrathecal Anti-Aquaporin 4 Antibodies. International Journal of Molecular Sciences, 2016, 17, 1407.	4.1	10
36	Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14781-14786.	7.1	59

#	Article	IF	Citations
37	Variable sensitivity to complement-dependent cytotoxicity in murine models of neuromyelitis optica. Journal of Neuroinflammation, 2016, 13, 301.	7.2	12
38	Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica. Journal of Neuro-Ophthalmology, 2016, 36, 238-245.	0.8	23
39	Placebo-controlled study in neuromyelitis opticaâ€"Ethical and design considerations. Multiple Sclerosis Journal, 2016, 22, 862-872.	3.0	63
40	Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. Science China Life Sciences, 2016, 59, 1270-1281.	4.9	47
41	The Ins and Outs of B Cells in Multiple Sclerosis. Frontiers in Immunology, 2015, 6, 565.	4.8	54
42	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 2015, 72, 815.	9.0	59
43	The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model. Experimental Neurology, 2015, 265, 8-21.	4.1	59
44	Re-evaluating the treatment of acute optic neuritis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 799-808.	1.9	29
45	Varicella Zoster Virus in Ischemic Optic Neuropathy. Ophthalmology, 2015, 122, 2142-2145.	5.2	9
46	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 2015, 85, 177-189.	1.1	3,275
47	ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis. Journal of the Neurological Sciences, 2015, 351, 174-178.	0.6	71
48	Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. Neurology, 2015, 84, 1948-1955.	1.1	156
49	The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations. Journal of Neuroinflammation, 2015, 12, 19.	7.2	48
50	Mutagenesis of the Aquaporin 4 Extracellular Domains Defines Restricted Binding Patterns of Pathogenic Neuromyelitis Optica IgG. Journal of Biological Chemistry, 2015, 290, 12123-12134.	3.4	33
51	Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid cause demyelination of spinal cord explants. Acta Neuropathologica, 2015, 130, 765-781.	7.7	76
52	B lymphocytes in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e104.	6.0	132
53	Update on biomarkers in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e134.	6.0	104
54	Analysis of Varicella-Zoster Virus in Temporal Arteries Biopsy Positive and Negative for Giant Cell Arteritis. JAMA Neurology, 2015, 72, 1281.	9.0	101

#	Article	IF	Citations
55	Evaluation of aquaporinâ€4 antibody assays. Clinical and Experimental Neuroimmunology, 2014, 5, 290-303.	1.0	106
56	Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions. Acta Neuropathologica, 2014, 127, 523-538.	7.7	38
57	Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G. Journal of Neuroinflammation, 2014, 11, 16.	7.2	53
58	Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nature Reviews Neurology, 2014, 10, 493-506.	10.1	220
59	Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. Acta Neuropathologica, 2013, 126, 699-709.	7.7	95
60	Neuromyelitis Optica IgG Causes Placental Inflammation and Fetal Death. Journal of Immunology, 2013, 191, 2999-3005.	0.8	90
61	Neuromyelitis optica IgG does not alter aquaporinâ€4 water permeability, plasma membrane M1/M23 isoform content, or supramolecular assembly. Glia, 2012, 60, 2027-2039.	4.9	47
62	Antiâ€“Aquaporinâ€4 monoclonal antibody blocker therapy for neuromyelitis optica. Annals of Neurology, 2012, 71, 314-322.	5.3	232
63	Intravenous Neuromyelitis Optica Autoantibody in Mice Targets Aquaporin-4 in Peripheral Organs and Area Postrema. PLoS ONE, 2011, 6, e27412.	2.5	73
64	Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Annals of Neurology, 2011, 70, 943-954.	5.3	142
65	Binding Affinity and Specificity of Neuromyelitis Optica Autoantibodies to Aquaporin-4 M1/M23 Isoforms and Orthogonal Arrays. Journal of Biological Chemistry, 2011, 286, 16516-16524.	3.4	161
66	Viruses and Multiple Sclerosis. Neuroscientist, 2011, 17, 659-676.	3.5	60
67	Evidence against Cellular Internalization in Vivo of NMO-IgG, Aquaporin-4, and Excitatory Amino Acid Transporter 2 in Neuromyelitis Optica. Journal of Biological Chemistry, 2011, 286, 45156-45164.	3.4	60
68	Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. Laboratoriums Medizin, 2010, 34, 1-12.	0.6	3
69	Live Cell Analysis of Aquaporin-4 M1/M23 Interactions and Regulated Orthogonal Array Assembly in Glial Cells. Journal of Biological Chemistry, 2009, 284, 35850-35860.	3.4	77
70	Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Annals of Neurology, 2009, 65, 639-649.	5.3	176
71	Intrathecal pathogenic antiâ€“aquaporinâ€4 antibodies in early neuromyelitis optica. Annals of Neurology, 2009, 66, 617-629.	5.3	516
72	Update on Inflammation, Neurodegeneration, and Immunoregulation in Multiple Sclerosis. Clinical Neuropharmacology, 2009, 32, 121-132.	0.7	82

#	Article	IF	Citations
73	CSF IgG heavy-chain bias in patients at the time of a clinically isolated syndrome. Journal of Neuroimmunology, 2008, 199, 126-132.	2.3	32
74	VH4 Gene Segments Dominate the Intrathecal Humoral Immune Response in Multiple Sclerosis. Journal of Immunology, 2007, 179, 6343-6351.	0.8	68
75	Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis. Neurological Research, 2006, 28, 291-298.	1.3	27
76	Screening Random Peptide Libraries with Subacute Sclerosing PanencephalitisBrain-Derived Recombinant Antibodies Identifies Multiple Epitopes in the C-Terminal Region of the Measles Virus Nucleocapsid Protein. Journal of Virology, 2006, 80, 12121-12130.	3.4	17
77	Developmental Neurogenetics and Neuro-Ophthalmology. Journal of Neuro-Ophthalmology, 2002, 22, 286-296.	0.8	11
78	Epstein-barr virus-associated acute autonomic neuropathy. Annals of Neurology, 1996, 40, 453-455.	5.3	55
79	Sustained long-term efficacy and safety of satralizumab in NMOSD. , 0, , .		0